In 2007 , Merck KGaA acquired the exclusive worldwide marketing rights from Oncothyreon and Merck KGaA is since then entirely responsible for the further clinical development of Tecemotide .
ADP NUM , PROPN PROPN VERB DET ADJ ADJ NOUN NOUN ADP PROPN CCONJ PROPN PROPN VERB SCONJ ADV ADV ADJ ADP DET ADJ ADJ NOUN ADP PROPN .